Biotechnology and Pharmaceutical Companies Borrow From Limited IT Resource Pool
The onset of technologically advanced software and hardware platforms for the biotechnology and pharmaceutical industries has resulted in more than a few drug manufacturers enlisting the talents of information technology professionals. Systems management issues between various protocols as well as the operating system functionality of cutting edge software have created an atmosphere where laboratory technicians spend a large portion of their time managing biotechnology infrastructures. While many larger firms already have information technology personnel that work exclusively on corporate related networks, few if any were called upon to bridge the gap between scientific software and traditional hardware. Most software manufacturers who offer genetic modeling or chemical composition software rarely consider the cross platform restrictions of their products, hence the need for well trained information technology professionals.
Throwing another wrench into the works is the development and widespread use of open source software. Open source software protocols are expansive and easily altered by nature. Many open source software developments carry no licensing restrictions. While the software itself can be extremely beneficial to biotechnology and pharmaceutical firms, the havoc it can wreak on hardware systems leaves much to be desired. While information technology professionals aren't likely to write or alter code for unilateral workability, they can be called upon to structure data transfers between open sources programs that will allow the information garnered from one to be placed into another without damage to the overall system.
Many educational providers are starting to offer IT degree programs dedicated to information technology development for the biotechnology and pharmaceutical industries. These programs train information technology personnel for the industry specific needs that often arise when dealing with cross platform data evaluation systems. As the complexities of software increase, so likely will the need for qualified IT professionals to make it run smoothly. Those who are already firmly entrenched in the IT world as well as those who plan to make a career of IT would do well to pay attention to the growing need for specialized technical personnel in this expanding market.
Earn your Degree in Information Technology or browse all online and ground schools Read other articles about online education.
Throwing another wrench into the works is the development and widespread use of open source software. Open source software protocols are expansive and easily altered by nature. Many open source software developments carry no licensing restrictions. While the software itself can be extremely beneficial to biotechnology and pharmaceutical firms, the havoc it can wreak on hardware systems leaves much to be desired. While information technology professionals aren't likely to write or alter code for unilateral workability, they can be called upon to structure data transfers between open sources programs that will allow the information garnered from one to be placed into another without damage to the overall system.
Many educational providers are starting to offer IT degree programs dedicated to information technology development for the biotechnology and pharmaceutical industries. These programs train information technology personnel for the industry specific needs that often arise when dealing with cross platform data evaluation systems. As the complexities of software increase, so likely will the need for qualified IT professionals to make it run smoothly. Those who are already firmly entrenched in the IT world as well as those who plan to make a career of IT would do well to pay attention to the growing need for specialized technical personnel in this expanding market.
Earn your Degree in Information Technology or browse all online and ground schools Read other articles about online education.

Use the feedback form below to submit your comments.

Use the form below to email this article to your friends.

- Schering-Plough Admits Lying To US Government
- Reno Jury Orders Wyeth to Pay $134 Million in Premarin Case
- Pharmaceutical Giant Pfizer Announces Job Cuts, Plant Closures
- Bayer 'put Asians in Danger of Hiv'
- Gates' Charity Shifts Policy
- RFID Pharmaceutical services
- Diseases of Rich Deprive Poor of Drugs
- Novartis Makes £4.4bn Move Into Cut-price Drug Making
- Investors Urge Drug Firms to Do More for World's Poor
- Aventis Braced for €60bn Bid From Its Smaller Rival
- War on Cheap Drugs
- Ruling Opens the Door for Cut-price Hiv Drugs
- Pfizer spikes cactus drug deal
- Bio-techs merge to cut costs
- Glaxo Cuts Price of Aids Drugs in Poor Countries
- In the Time It Takes You to Read This Article Pfizer Will Make $250,000. So Does It Have a Duty to Provide Cheap Drugs to the Poor?
- Bayer insurance may not cover claims




